Print Page  Close Window

Investor Relations Home

Stock Information
Corporate Profile

Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to addressing unmet needs of patients by bringing innovative solutions to the field of dermatology. The company is in late-stage clinical development of two lead products based on the company’s first-in-class topical Minocycline Foam: FMX101, for the treatment of moderate-to-severe acne, and FMX102, for the treatment of impetigo. Having completed Phase II clinical trials of these product candidates, the company expects ... More >>

Recent NewsMore >>
08/08/17Foamix Reports Second Quarter 2017 Financial Results and Provides Business UpdatePrinter Friendly Version
08/03/17Foamix Announces Dosing of First Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101Printer Friendly Version
07/26/17Foamix Pharmaceuticals Second Quarter Financial Results Conference Call & Webcast Scheduled for August 9Printer Friendly Version
06/29/17Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive OfficerPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Foamix Pharmaceuticals Ltd posts new information to the site. Just enter your e-mail address and click Submit.